Background: Amphotericin B (AmB) as a liposomal formulation of AmBisome is the first line of treatment for the disease, visceral leishmaniasis, caused by the parasite Leishmania donovani. However, nephrotoxicity is very common due to poor water solubility and aggregation of AmB. This study aimed to develop a water-soluble covalent conjugate of gold nanoparticle (GNP) with AmB for improved antileishmanial efficacy and reduced cytotoxicity. Methods: Citrate-reduced GNPs (~39 nm) were functionalized with lipoic acid (LA), and the product GNP-LA (GL~46 nm) was covalently conjugated with AmB using carboxyl-to-amine coupling chemistry to produce GNP-LA-AmB (GL-AmB~48 nm). The nanoparticles were characterized by dynamic light scattering, transmission electron microscopy (TEM), and spectroscopic (ultraviolet-visible and infrared) methods. Experiments on AmB uptake of macrophages, ergosterol depletion of drug-treated parasites, cytokine ELISA, fluorescence anisotropy, flow cytometry, and gene expression studies established efficacy of GL-AmB over standard AmB. Results: Infrared spectroscopy confirmed the presence of a covalent amide bond in the conjugate. TEM images showed uniform size with smooth surfaces of GL-AmB nanoparticles. Efficiency of AmB conjugation was~78%. Incubation in serum for 72 h showed <7% AmB release, indicating high stability of conjugate GL-AmB. GL-AmB with AmB equivalents showed~5-fold enhanced antileishmanial activity compared with AmB against parasiteinfected macrophages ex vivo. Macrophages treated with GL-AmB showed increased immunostimulatory T h 1 (IL-12 and interferon-γ) response compared with standard AmB. In parallel, AmB uptake was~5.5 and~3.7-fold higher for GL-AmB-treated (P<0.001) macrophages within 1 and 2 h of treatment, respectively. The ergosterol content in GL-AmB-treated parasites was~2-fold reduced compared with AmB-treated parasites. Moreover, GL-AmB was significantly less cytotoxic and hemolytic than AmB (P<0.01). Conclusion: GNP-based delivery of AmB can be a better, cheaper, and safer alternative than available AmB formulations.
Introduction
Metallic nanoparticles (NPs) and their compounds synthesized by chemical or biological methods have been used for treatment and detection of diseases since ancient times. 1 Green synthesis of silver nanoparticles (AgNPs) and gold nanoparticle (GNPs)
is most common due to their reduced cytotoxicity. 2 AgNPs synthesized by green of bactericidal action with their ability to penetrate biological membranes. 16 Here, we report the synthesis, characterization, and efficacy of GL-AmB, a covalent conjugate of GNP with amphotericin B (AmB) against parasite Leishmania donovani (LD). AmB is a polyene antibiotic with poor water solubility and high toxicity due to its self-aggregation. 17 It was first licensed in the 1950s. 18 Since then, AmB has been extensively used as a deoxycholate formulation (Fungizone) in a micellar form to treat systemic fungal infections. 19 However, due to severe nephrotoxicity, use of Fungizone became limited 20 against visceral leishmaniasis (VL), 21 a disease caused by Leishmania parasite species 22 that becomes fatal if untreated. This prompted development of several lipid-based complexes of AmB (AmBisome, Abelcet, and Amphocil) with improved AmB delivery and reduced cytotoxicity 23 for the treatment of leishmaniasis. However, lipid-based complexes of AmB bring high cost in treatment for patients with leishmaniasis 24 and systemic fungal diseases 25 compared to standard AmB or AmB-deoxycholate formulation. In parallel, micelle-based 26 and NP-based 27, 28 AmB delivery with improved antileishmanial efficacy showed promise as an alternative to costly liposomal formulations. Novel NP-based AmB formulations combined with polysaccharides, 29 dendrimers, 30 iron NPs, 31 AgNPs, 32, 33 and carbon nanotubes 34 were developed. AmB derivatives with modified functional groups showed more enhanced and specific binding toward fungal ergosterol than cholesterol 35 with increased ion channel and fungicidal activity. 36 Therefore, treatment with a combination of NPs with AmB and/or AmB derivatives could be a very effective strategy for improving the efficacy of and reducing the cytotoxicity of AmB. AmB nanoemulsions against experimental VL 37, 38 and AmB coated with polymeric NPs had shown efficacy in oral delivery of AmB in a mouse model of VL. 39 Photo-induced antileishmanial activity was observed with AmB-AgNPs which were synthesized using plant phytochemicals. 40 Improved photodynamic therapy was observed for GNP-conjugated nanorods over nanospheres, indicating the imporatance of NP shape in efficacy. 41 Although there are growing developments of NPs as antileishmanial agents, 8, 28, 42 there is no report yet about covalent conjugation or functionalization of GNPs with AmB or AmB derivatives for enhanced efficacy against LD. Leishmaniasis, the second largest infectious disease after malaria and one of the "most neglected" diseases, is spread by 23 Leishmania species in more than 98 countries. Among all types, the VL caused by LD is life threatening and is most difficult to control. As per WHO report, a total of 0.7-1.0 million new leishmaniasis cases are estimated with an alarming 26,000-65,000 death toll every year. 43 Herein, we present the synthesis of GL-AmB, where the -COOH group present in the linker (lipoic acid (LA)) was used to conjugate with the -NH 2 group present in the mycosamine ring of AmB through amide linkage. The mechanism of action of GL-AmB was evaluated, with naked AmB as a comparative arm against LD.
Materials and methods Materials
M-199, RPMI-1640, and yeast peptone dextrose medium, HAuCl 4 •3H 2 O, Giemsa dye, Trypan blue, MTT, 2′,7′-dichlorodihydrofluorescein diacetate dye, N-acetyl l-cysteine (NAC), diphenyleneiodonium chloride, proteinase K, ergosterol (ERG), diphenyl hexatriene (DPH), RNase A, Griess reagent, 2,4-dinitrophenylhydrazine, TRIZOL, nitro blue tetrazolium, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), lipoic acid, sulfo-N-hydroxy succinamide (NHS), AmB as Fungizone, the Glutathione Colorimetric Assay Kit, the lactate dehydrogenase (LDH) assay kit, the Apoptosis Detection Kit, and all solvents were from SigmaAldrich Co. (St Louis, MO, USA). Trisodium citrate was from Merck (USA). The QIAamp DNA Mini kit and RNeasy Mini Kit were from Qiagen (NV, Venlo, the Netherlands). The cDNA synthesis kit was from Hoffmann-La Roche (Basel, Switzerland). The cytokine ELISA kit was obtained from BD Biosciences (San Jose, CA, USA) for mouse interferon (IFN)-γ, IL-12, and IL-10, respectively. The RAW 264.1 THP-1 cell line was obtained commercially from the National Cell Repository, NCCS, Pune, India. For the hemolysis assay, blood samples from healthy volunteers were collected based on ethical approval from RMRIMS-Patna (Reference no. 21/RMRI/EC/2017) and the donor's written informed consent.
Methods

Synthesis and conjugation of GNP with AmB
Reactions were done at room temperature unless mentioned. GNPs were synthesized according to the method of Turkevich et al 44 by reduction of HAuCl 4 •3H 2 O solution (0.5 mM) in 0.05% trisodium citrate after dilution with double-distilled water (DDW) and heating at 75-80°C for 5-10 min. Synthesis of red GNPs was confirmed by measuring absorbance at 530 nm. The concentration and molar extinction coefficient of GNPs vary with size during reduction of HAuCl 4 . Therefore, the absolute amount of Au (μg/mL), rather than the molar concentration, was used as a measure of GNP concentration. GNPs were functionalized with LA and then conjugated with AmB using EDC/NHS coupling chemistry 45 with a few modifications. GNP solution (10 mL) was mixed with 0.1 mL (0.35 M) of LA and incubated for 12 h at 4°C with constant stirring. The mixture was centrifuged at 12000×g for 15 min, washed with phosphate buffer (PB) (10 mM Na phosphate, pH 7.2), and a pellet of GL was suspended in 5 mL of PB. GL (1.25 mL) was mixed with 45 μM EDC and 40 μM NHS, and incubated for 3 min. Then, 0.1 mL of 50 mg/mL of AmB (dissolved in dimethylsulfoxide (DMSO)) and 0.35 mL of DDW were added. The mixture (~1.75 mL) was kept at constant stirring for 2 h to allow formation of a covalent amide bond between GL and AmB. 46 The reaction mixture was centrifuged, washed 10 times with PB, and then stored in a suspension of 1 mL of PB at 4°C for further use. After measuring the amount of unbound AmB by ultraviolet (UV) spectroscopy, the ratio of GNP:AmB in the GLAmB conjugate was found to be 245 μg/mL:4.2 mg/mL (4.55 mM AmB), indicating~84% conjugation efficiency of AmB in GL-AmB. Several batches of GL-AmB were prepared similarly and stored in PB buffer.
Quantification of AmB in GL-AmB by HPLC
Efficiency of conjugation of AmB in GL-AmB was measured by HPLC determination of AmB at 408 nm by UV detector. 47 GL-AmB (~4.2 mg/mL of AmB) was diluted 
Characterization of GL-AmB NPs
NPs were analyzed by UV-visible spectrophotometer, dynamic light scattering, Fourier transform infrared spectroscopy (FT-IR), and TEM. The hydrodynamic diameter, polydispersity index (PDI), and zeta potential were determined on a Beckman Coulter (Brea, CA, USA) Delsa nano submicron particle size and zeta potential analyzer as per standard procedures. For FT-IR analysis, purified NPs (GL and GL-AmB) and powdered AmB were pelletized with KBr and scanned over a range of 4000-400 cm −1 in a PerkinElmer Inc.
(Waltham, MA, USA) Spectrum 400 spectrometer. NPs were processed and analyzed by TEM (JEOL-JEM 2010; JEOL, Tokyo, Japan) analysis as described. 48 Briefly, NPs (100 µM) were diluted with DDW 1:1. Further, 20 µL of sample was loaded on carbon-coated copper grid without gold coating and air dried for 10 min under vacuum. The grid chamber was placed in the TEM room and incubated in the dark at 10-20°C for 2 h. Finally, the grid chamber was loaded on the TEM stage for analysis and images were captured from different zones with different resolution. The powder X-ray diffraction (pXRD) analysis was carried out for GLAmB in a Rigaku TTRX-III diffractometer using Cu-K α (λ=1.54 Å) as the X-ray radiation source and a scan range of 10-80°.
Stability studies of GL-AmB conjugate
Stability of GL-AmB (100 μM) was measured by measuring the release of free AmB in PBS buffer (PB containing 150 mM NaCl) and in freshly isolated human plasma at pH 7.4. 49 The incubation mixture of GL-AmB and human serum or PBS with final AmB concentration of 100 μM was incubated at 37°C for 72 h. After 4, 8, 12, 24, 48 , and 72 h, the mixture was centrifuged at 15000×g for 10 min and absorbance of supernatant was taken at 360 nm. The percentage of AmB release was estimated 47 by considering the absorbance of 100 μM standard AmB as 100%. GL-AmB present in PBS or plasma was treated with proteinase K (1 μg/mL) for 1, 2, 4, 6, 8, and 12 h to accelerate cleavage of the amide bond in GLAmB when required.
In vitro assay against promastigotes LD (MHOM/IN/1983/AG83) promastigotes were cultured as described. 50 Log phase cells (1×10 6 cells/ml) were treated with GNP/GL (0.5, 1, 2.5, 5, and 10 μg/mL) and AmB/GLAmB (0.5, 1, 5, 20, 50, and 100 nM) for 3-4 days and cell viability measured by Trypan blue exclusion and MTT reduction method after every 24 h using standard procedures. After 48 h, the drug concentration showing 50% killing of the parasite was considered the IC 50 for that drug. Drug-treated cells were preincubated with 1 mM NAC when required.
51
Assay against intracellular amastigotes in macrophages RAW 264.1 cells were maintained in RPMI-1640 medium and infected with promastigotes as described. 33 Parasiteinfected macrophages, grown for another 24 h, were treated with different concentrations of GNP/GL (0.5, 1, 2.5. 5, and 10 μg/mL) and AmB/GL-AmB (20, 50, 100, 250, 500, and 1000 nM) for 48 h. Chamber slides were washed and supplemented with fresh medium and kept in a CO 2 incubator for another 12 h. Untreated parasite-infected macrophages were used as control. Amastigotes from 100 macrophage nuclei per well were counted, at least, under the oil immersion objective of a light microscope (Eclipse TS100; Nikon Corporation, Tokyo, Japan) after methanol fixation and Giemsa staining of the slides.
Cytotoxicity assays
Cytotoxicity was measured against human THP-1 cells by MTT assay. Briefly, THP-1 cells were cultured with RPMI-1640 medium in 6-well plates (2×10 6 cells/well) and treated with GNP/GL (2.5, 5, 10, and 25 μg/mL) and AmB/GL-AmB (2.7, 5.5, 11, 22, and 35 μM) for 48 h and cell viability was measured as described. 52 
Hemolysis assay
Human erythrocytes were incubated (4×10 8 cells/mL in PBS) in the presence of GNP/GL (2.5, 10, and 25 μg/mL) and AmB/GL-AmB (1, 54, 80, and 108 μM) for 4 h at 37°C. The samples were centrifuged at 1500×g for 5 min and the absorbance of supernatant was measured at 560 nm. Relative hemolysis was measured 52 by considering hemolysis of 100
μM AmB-treated erythrocytes as 100%. were analyzed by HPLC as described earlier.
Measurement of intracellular thiol
Promastigotes (2×10 6 cells/well) were treated with GNP (10 μg/mL) and AmB/GL-AmB (0. 
Measurement of protein carbonylation by spectrophotometric assay
AmB-mediated stress causes oxidative modification of the amino acids of proteins to carbonyl groups which were derivatized with 2,4-dinitrophenylhydrazine (DNPH) and then measured by spectrophotometric assay. 61 Briefly, promastigotes (1×10 7 cells/ml) were treated with GNP (2.5
and 10 μg/ml), AmB/GL-AmB (0.05 and 0.2 μM) for 6 and 12 h. Cells were then harvested, lysed and protein carbonylation content was measured as described. 62 
Lipid peroxidation assay
Parasites (5×10 6 cells/well) were taken in 24 wells plate and treated with different concentrations of GNP (2.5, 10 and 25 µg/ml), AmB/GL-AmB (0.05-0.35 µM) for 12 h. In parallel, treated cells were also incubated with ROS inhibitor, NAC (1mM). Untreated cells were taken as negative control. Lipid peroxidation products were measured as described. 51 
Statistical analysis
The statistical analysis was done by one-way and two-way ANOVA using Graphpad Prism software (version 5.00; GraphPad Software Inc., La Jolla, CA, USA). The results were measured as mean±SD of at least three independent experiments. The results were shown as approximate mean values. Differences between group data (specially between AmB and GL-AmB) were considered statistically significant and highly significant when P<0.05 and P<0.001, respectively.
Results
Synthesis and characterization of GL-AmB conjugate
By HPLC measurement, the amount of AmB detected in GL-AmB was~3.9 mg/mL (~4.23 mM, AmB input was 5 mg/mL) which is equivalent to~78% conjugation efficiency (compare Figure S1A and B) based on the AmB standard curve ( Figure S1C ). This data correlated well with the measured~84% conjugation efficiency by UV spectroscopy (data not shown). Therefore, there is conjugation of 16 μg of AmB per microgram of Au, indicating multimolecular association of AmB with a single molecule of Au NP ( Figure 1A ). For schematic presentation, 16 molecules of AmB in conjugation with 1 GNP are shown in Figure  1A , although the exact molar ratio of AmB:GNP in GLAmB is unknown. The UV absorption spectrum of monomeric AmB is characterized by four bands with peaks around 344-350 (peak I), 363-368, 383-388, and 406-412 nm (peak IV). The ratio between the absorbance intensities of peak I and peak IV was used to measure the degree of aggregation of AmB. 63 The higher the ratio of peak I/IV, the higher the degree of aggregation. UV spectra of GL-AmB showed peaks for both AmB (340-410 nm) and GNP (~530 nm), but the intensity of peak I was greatly reduced and the intensity for peak IV was increased. In fact, the AmB-specific peaks of GL-AmB were very similar to AmB dissolved in DMSO, a monomeric disaggregated form of AmB ( Figure 1B ). Hence, in GL-AmB, AmB becomes aggregation free and water soluble. Further, TEM images confirmed the monomeric and spherical size of GL-AmB ( Figure 1C , i and ii) and the visible presence of an AmB layer on GL-AmB (indicated by double arrow in Figure 1C , ii). The selected area electron diffraction pattern confirmed the presence of GNP in GL-AmB ( Figure 1C , iii). An increase in hydrodynamic radii of the GNP was observed after its capping with LA to form GL (~46 nm, Figure 2A ). However, further conjugation of GL with AmB did not change the hydrodynamic radii appreciably (GL-AmB~48 nm). Interestingly, the PDI decreased after functionalization of GL with AmB, indicating a narrower size distribution due to further stabilization of NPs by AmB ( Figure S2B ). Increased negative zeta potential of GL-AmB (−21.16 mV, Figure S2A ) compared to GNP (−13.94 mV) indicated the formation of a stable entity with less chance of agglomeration. Conjugation of AmB with GL was further confirmed by FT-IR analysis ( Figure 2B ). In GL-AmB, IR peaks at 1642 cm −1 for C=O stretching (amide I) and at 1565 cm
for N-H bending (amide II), along with the presence of other characteristic peaks of AmB, confirmed successful amide bond formation between the -COOH group of GL and the -NH 2 group of AmB. GL-AmB was also examined through pXRD measurement ( Figure S3 ). This revealed Bragg's diffraction at 38.2°, 47.7°, 65.3°, and 77.1°which were attributed to (111), (200), (220), and (311) sets of lattice planes reflecting the face centered cubic structure of metallic gold. 48 The pXRD pattern thus unveiled the crystalline nature of GNP in GL-AmB.
Stability of GL-AmB conjugates
AmB forms a single amide bond with LA in GL to give GL-AmB. Therefore, the stability of GL-AmB is dependent on the stability of this amide bond. We measured stability of GL-AmB by AmB release assay in PBS/plasma after measuring UV spectra at 360 nm since AmB gives the strongest peak at 360 nm. A similar kind of release assay was done earlier for polyethylene glycol-AmB conjugate. 49 This is possible because the molar extinction coefficient of AmB is very high 64 and, therefore, gives high sensitivity in detection. We tested the stability of GLAmB by AmB release in the presence and absence of proteinase K, known for its high protease activity with a specificity for cleaving peptide bonds, in PBS and in blood plasma at pH 7.4. In the absence of proteinase K, after 72 h of incubation <7% AmB was detected in plasma ( Figure 3A ) and <1% AmB was detected in PBS. Interestingly, treatment of GL-AmB with proteinase K released >20% and >60% AmB within 1 and 4 h, respectively, indicating, further, the presence of a stable amide bond in GL-AmB ( Figure 3B ). However, no significant increase in AmB release was found after 6 h.
Antileishmanial activity against promastigote and amastigote forms of L. donovani
The IC 50 for GNP and GL after 48 h was~2.5 μg/mL against promastigotes ( Figure 4A ) and~5 μg/mL against amastigotes ( Figure 4B ). GL-AmB (IC 50~2 0 nM) showed increased antileishmanial efficacy compared with AmB (IC 50~5 0 nM) against promastigotes at all indicated doses ( Figure 4A and B). The IC 50 after 48 h for GL-AmB (~100 nM) was five times lower than for AmB (~500 nM, Figure 4C and D) against amastigotes. Therefore, conjugate GL-AmB is more potent than AmB and the presence of linker in the GNP has no effect on improved efficacy. Mere addition of GNP (0.53 pg/mL) and AmB (20 nM) (equivalent to the amount present in 20 nM GL-AmB) in the promastigote assay showed an effect similar to naked AmB in antileishmanial efficacy (data not shown).
So, efficacy of GL-AmB against LD is due to the presence of multimolecular AmB conjugated with GNP. Time (h) Figure 3 Amount of AmB released from GL-AmB (0.1 mM) was measured by UV absorbance after incubation in PBS and in blood plasma for 48 h (A). Amount of AmB released from GL-AmB (0.1 mM) after incubation in PBS/blood plasma with or without proteinase K (1 μg/mL) for 6 h (B). Data presented in % scale where UV absorbance of 0.1 mM AmB was considered 100%. Abbreviations: AmB, amphotericin B; GL, GNP-lipoic acid product; GNP, gold nanoparticle; UV, ultraviolet. and~53 µM, respectively, at similar time points. With 20 and 50 nM doses of AmB, survival of promastigotes after 72 h (61% and 50%, Figure S4C ) and 96 h (63% and 54%, Figure S5C ) shows no significant change with killing efficacy compared to 48 h (71% and 51%, Figure 4B ). For GL-AmB with similar doses, survival of promastigotes after 72 h (44% and 27%) and 96 h (41% and 29%) shows, also, insignificant change in killing efficacy compared to 48 h (50% and 27%). However, at every time point, GL-AmB is more efficacious than AmB. For amastigotes, very similar patterns were observed. Therefore, antileishmanial activity data for promastigotes/amastigotes after 72 h and 96 h showed no significant change in killing efficacy with increasing dose ( Figure S4 and S5). This is likely because AmB is only stable for 3 days in cell culture medium, as suggested by different manufacturers.
Cytotoxicity and hemolytic studies
For GNP and GL, the concentration showing 50% killing of macrophages compared to untreated control after 48 h (CC 50 value) was~10 μg/mL. For AmB and GL-AmB, the CC 50 values were~8 and~35 μM, respectively. At an 11
μM dose (~22 times IC 50 of AmB on amastigotes), AmB and GL-AmB showed~28% and~70% survival of THP-1 cells (P<0.001, Figure 5A and B). When THP-1 cells were treated with 22 µM of AmB and GL-AmB, survival was 18% and~63%, respectively. After 72 h with a 35 µM dose, THP-1 survival was~2% for AmB-treated cells but 44% for GL-AmB-treated cells ( Figure S6 ). Therefore, GL-AmB is significantly less cytotoxic than AmB (P<0.001) and this was due to conjugation of AmB over GNPs and not due to the presence of linker in GNPs.
Both, GNPs and GL showed very similar and high hemolytic activity. At 2.5 μg/mL, >40% hemolysis is observed with GNP/GL. At a 1 μM dose, AmB showed 32% hemolysis but GL-AmB showed only~5% hemolysis (P<0.001, Figure 5C and D). Hemolysis was~63% and 83% at 54 µM and 80 µM doses of AmB. Under similar conditions, hemolysis for GL-AmB-treated erythrocytes was 17% and~33% (Figure 5D, P<0.001 ). At the highest tested dose (108 μM), GL-AmB showed significantly reduced hemolysis compared to AmB (48% vs 112%). Therefore, hemolytic activity of both GNPs and AmB was significantly reduced due to conjugation of AmB with GNP. 
AmB and ergosterol determination by HPLC
Macrophages were treated with a high dose of AmB/GL-AmB (300 μg/mL/10 6 macrophages) for 1-24 h to see the difference in AmB uptake, if any, between AmB and GL-AmB. After 1, 2, and 4 h, AmB uptake was significantly higher for GL-AmBtreated cells than for AmB-treated cells as measured by HPLC (represented as nanograms of AmB/milligrams of protein, Figure 6A ). AmB uptake was~5.5-fold (~560 vs~95), 3.7-fold (~780 vs~209), and~2.9-fold (~875 vs~311) higher for GL-AmB-treated cells compared to AmB-treated cells after 1, 2, and 4 h of treatment, respectively (P<0.001, Figure 6A ). AmB uptake was reduced to~1.3-fold after 6 h (~612 vs 472 for GL-AmB and AmB, respectively), possibly due to high AmB-mediated toxicity leading to reduced macrophage uptake. Consequently, the difference in AmB uptake was less significant between GL-AmB and AmB-treated cells after 12 and 24 h of treatment.
AmB binds ERG with higher efficacy than cholesterol 35 and AmB-resistant LD parasites are associated with changes in gene expression or mutation in genes involved in the ERG biosynthesis pathway. 65, 66 The ERG content of samples were measured based on the ERG standard curve with a retention time (RT) of 7.31 min in HPLC ( Figure 6B ). The ERG content was~1.9-fold lower in GL-AmB-treated cells compared to AmB-treated cells (34.2 μg/mL vs 65.1 μg/mL, Figure 6D and E) and~3.4-fold lower compared to untreated cells (116.4 μg/mL, Figure 6C ). The peak with RT of 2.66 min ( Figure 6D ) was possibly due to sterol, cholesta-5,7,24-triene-3β-ol, which was the major sterol in the AmB-resistant LD strain due to inhibition of enzyme SCMT (S-adenosyll-methionine:C-24-Δ-sterol methyltransferase) and consequent lack of C-24 transmethylation of C-27 sterols. 66 
Determination of thiol content
After 2, 4, and 6 h, the GSH content in GL-AmB-treated (0.5 μM) parasites was~1.7,~5 and~3-fold lower (P<0.001) compared to AmB-treated parasites, respectively ( Figure 7A ). However, the reduction in GSH content becomes insignificant after 12 h.
Fluorescence anisotropy by DPH assay
The FA value of GL-AmB-treated (0.5 μM) parasites was~1.3 (P<0.01) and~1.8 times (P<0.001) lower ( Figure 7B ) than that of AmB-treated parasites after 6 and 12 h, respectively. The membrane of GL-AmB-treated cells was, therefore, more fluidic than that of AmB-treated cells.
Measurement of membrane leakage by LDH assay
Increased membrane damage, leading to necrosis, is associated with extracellular release of LDH. At 0.5 μM concentration, LDH release was~71% and~38% after 6 h for GL-AmB and AmB-treated cells, respectively ( Figure 7C , P<0.001). Interestingly, after 12 h under similar treatment conditions, the difference in LDH release is insignificant (78% and 87% for AmB and GL-AmB, respectively, Figure 7D ). GNP at 25 μg/mL concentration showed 37% LDH release. Upon treatment with H 2 O 2 , which causes apoptosis, the amount of LDH release was <4%. So, GL-AmB is more necrotic than AmB against LD.
FACS analysis and DNA fragmentation assay
A necrotic or apoptotic mode of cell death was observed in LD after treatment with AmB and AmB formulations. 51, 67 In FACS analysis, the percentage of PI + and AV + promastigotes was taken as necrotic and apoptotic cells, respectively. Therefore, the increase in the ratio of percentage of PI + /AV + cells was an indicator of increased necrosis. The ratio was 61 for GL-AmB and~7 for AmB ( Figure 8C , P<0.001) when parasites were treated with 0.5 µM of AmB/GL-AmB. At the 0.25 µM treatment condition, the ratio was~40 and~6 for GL-AmB and AmB, respectively. Hence, GL-AmBmediated parasite death is more necrotic than apoptotic ( Figure 8A ). Further, no significant DNA laddering were observed in AmB and GL-AmB-treated samples (0.05 and 0.15 μM), confirming the absence of apoptosis under these conditions where H 2 O 2 -treated cells, used as apoptotic control, 59 showed significant DNA laddering as expected ( Figure 8B ).
In vitro activity against C. albicans Against C. albicans, IC 50 of GL-AmB and AmB was~2 μM and~8 μM, respectively indicating~4-fold improvement in antifungal efficacy ( Figure S7 ). The IC 50 of citrate-reduced GNP was found to be~40 μg/ml. Therefore, GL-AmB is more efficacious than AmB against, both, parasites and fungus. Time (h) 6 1 2
Figure 7 Treatment of parasites with nanoparticles and AmB followed by measurement of GSH (A), determination of fluorescence anisotropy values of DPH-labelled parasites (B), and measurement of membrane leakage by LDH assay after 6 h(C) and 12 h (D)
. 1% Triton-X-100-(Tx-100)-treated and H 2 O 2 -treated (0.1-0.2 mM) cells were used as positive and apoptotic controls, respectively. Note: *P<0.05; **0.05<P<0.01; ***0.01<P<0.001. Abbreviations: AmB, amphotericin B; DPH, diphenyl hexatriene; GL, GNP-lipoic acid product; GNP, gold nanoparticle; GSH, reduced glutathione; LDH, lactate dehydrogenase; PCR, polymerase chain reaction; HPLC, high pressure liquid chromatography; NS, non-significant.
Protein carbonylation assay
Protein carbonylation, which is a measure of oxidative stressmediated damage caused by AmB, was higher in GL-AmBtreated cells after 6 h but almost similar after 12 h ( Figure S5B ) compared to AmB-treated cells. After 6 h of treatment, protein carbonylation was~1.7 fold more for GL-AmB than AmBtreated parasites ( Figure S5A ). The amount of protein carbonylation caused by GL-AmB was almost comparable to 100 μM H 2 O 2 -treated cells after 6 h.
Lipid peroxidation measurements
High levels of free radicals or ROS can inflict direct damage to lipids specially to polyunsaturated fatty acids. It generates high levels of lipid peroxyl radicals and hydroperoxides which causes cell death by apoptotic or necrotic mode. 62 Lipid peroxidation products were higher in GL-AmB-treated cells than AmB-treated cells at all indicated doses (P < 0.05, Figure S5C ).
Cytokine analysis by ELISA and semiquantitative PCR
Stimulation of T h 1-cell-associated immune responses, mediated by IL-12 and IFN-γ, enhanced the antileishmanial effect of AmB in LD-infected animals. 30, 68 Significant upregulation in the levels of T h 1 (IL-12 and INF-γ) and downregulation of T h 2 (IL-10) cytokines were observed after GNP, AmB, and GL-AmB treatment in LD-infected macrophages compared to untreated control. After 12 and 24 h, GL-AmB showed~2.7 and~3.4-fold elevation of the IFN-γ level (P<0.001) compared to untreated control ( Figure 9A ). Under similar conditions, AmB-treated macrophages showed~2.2 and~2.5-fold increase in IFN-γ level. However, elevation of the IFN-γ level reduced to~2 and~1.6-fold after 48 and 72 h, respectively, for GL-AmB-treated cells compared to untreated control. The level of IL-12 was~3.4 and~3.7-fold increased for GL-AmB whereas for AmB the elevation was~2.1 and 1.6-fold after 12 and 24 h, respectively, compared to untreated control ( Figure 9B ). IL-12 release was significantly higher for GL-AmB-treated cells compared to untreated control even after 36 h (~3.1-fold) and 48 h (~3.5-fold). Under similar conditions, the level of IL-12 release was~1.25 and 1.4-fold for AmB-treated cells compared to untreated control. Further, the decrease in IL-10 cytokine level was more significant for GL-AmB-treated than for AmB-treated macrophages after 12 h (~3.9 vs~2.3-fold), 24 h (~1.9 vs 3.1-fold), 36 h (~2.6 vs 1.5-fold), and 48 h (~2.4 vs 1.5-fold) ( Figure 9C ). Therefore, GL-AmB caused more immunostimulatory effect than AmB by increasing the T h 1 and decreasing the T h 2 cytokine levels significantly. Interestingly, citratereduced GNP also significantly increased the level of T h 1 (~2.0 and~2.5-fold higher IFN-γ after 12 and 24 h, respectively) and decreased the level of T h 2 cytokine (~2.0 and 2.2-fold reduced IL-10 after 12 and 24 h, respectively) compared to untreated control. The change in macrophage cytokine level after GL-AmB/AmB treatment was also confirmed by semiquantitative PCR of genes specific for T h 1 and T h 2 cytokines. The IFN-γ level was~3.2 and~1.9-fold upregulated in GL-AmB and AmB-treated cells, respectively, compared to untreated control ( Figure 9D , Table 1 ). For IL-12, the up-regulation was~2.5 and~2.0-fold under the same conditions. For IL-10, the mRNA level was down-regulated by~2. respectively, compared to untreated control. Therefore, mRNA expression levels of T h 1 and T h 2 cytokines showed patterns similar to cytokine ELISA of GL-AmB and AmBtreated macrophages. For GNP, we found~2.4-fold upregulation of IFN-γ but no significant change in IL-12 mRNA level compared to untreated control ( Figure 9D ).
Discussion
Discovery of new liposomal AmB formulations 23 reduces the cytotoxicity of AmB but comes with limitations of a narrow therapeutic index or high cost for lipid formulations. 69 AmBisome contains a liposomal membrane consisting of hydrogenated soy phosphatidylcholine, cholesterol, and distearoylphosphatidylglycerol along with other ingredients. Due to the presence of these costly lipid molecules, the cost of AmBisome formulation becomes very high and, therefore, a main barrier to widespread use in the pharmacotherapy of leishmaniasis in developing countries. 24, 70 In fact, to check the feasibility of cost reduction in VL treatment, a single-dose liposomal AmB was compared with 15 alternate-day infusions of amphotericin B deoxycholate in a clinical trial. 71 Therefore,
water-stable and well-dispersed aqueous solutions of AmB with low toxicity and reduced manufacturing costs remain a priority. New derivatives of AmB for improved water solubility, antifungal efficacy, and reduced cytotoxicity were synthesized. 52, [72] [73] [74] In general, the single amine and single carboxylic group of AmB were preferred for chemical modification 75, 76 where modification of the AmB amine group was found to be more effective in reducing the cytotoxicity 77 without compromising efficacy 52 against fungus. GNP was functionalized with a linker LA to chemically conjugate the amine group of AmB with the carboxylic group of LA to produce GL-AmB ( Figure 1A ). The conjugate became water soluble (~5 mg/mL). UV spectroscopy of GL-AmB is very similar to a DMSO-soluble nonaggregated form of AmB (Figure 1B) , indicating the monodisperse nature of GL-AmB further confirmed by TEM analysis ( Figure 1C ) and observed higher negative zeta potential values ( Figure S2 ) of GL-AmB compared to AmB. The IC 50 for GL-AmBcompared to AmB was 5-fold reduced (~100 nM vs~500 nM) against amastigotes ( Figure 4D ). Apart from its efficacy against LD (~2.5-fold reduction in IC 50 against promastigotes, Figure 4C ), GLAmB was, also, found to be more potent than AmB against fungus Candida albicans (~4-fold reduction in IC 50 , Figure  S7 ) in vitro. However, there is no significant change in killing efficacy for promastigotes or amastigotes after 48 h with increasing doses, possibly due to instability of AmB in cell culture medium after 72 h. HPLC analysis showed increased macrophage uptake for GL-AmB (>5, >3.5, and >2.5-fold after 1, 2, and 4 h, respectively, Figure 6A ) compared to standard AmB. Macrophage uptake of AmB/AmB formulation up to 24 h was also done earlier with human monocyte cells THP-1 55 and human macrophages J774, 72 where uptake of different AmB formulations was clearly shown with significant differences. Macrophage uptake correlates well with the TEM image of polyphenolfunctionalized GNPs' fast uptake in macrophages, 48 indicating a possible advantage of GNP-based drug delivery in VL, a disease where the parasite primarily infects the macrophages of the liver and spleen. The RT of AmB and GLAmB was 3.41 and 3.52 min, respectively, in HPLC ( Figure  S1A and B) and, therefore, the peak of AmB obtained (RT=3.44 min) during macrophage uptake studies for GLAmB could be due to a mixture of free AmB (released after cleavage of amide bond by macrophage peptidases 78 ) and AmB present in intact GL-AmB. For GNP, the CC 50 against THP-1 cells was~10 μg/mL, which was just 2 times its IC 50 on amastigotes. This explains, possibly, why citrate-reduced GNPs are not reported as effective antileishmanial agents although green-synthesized GNPs show promise for the same. 48, 79, 80 Observed cytotoxicity of GNPs depends on the size, surface chemistry, and type of cell where it was used. 81 The mechanism of cytotoxicity arising for citratereduced GNPs is not yet established but studies have shown that increased sodium citrate on the surface of GNPs was more cytotoxic for alveolar epithelial cell lines. 82 Oxidative stress-mediated toxicity was reported for citrate-reduced GNP-induced release of nitric oxide into serum. 83 GNPs coated with citrate have shown increased internalization in macrophages with decreased glutathione level. 84 So, it is likely that change in redox homeostasis and binding of serum proteins 85 causes cytotoxicity of citrate-reduced GNPs against macrophages. Reduced GSH, a potent antioxidant which controls cellular redox status, was significantly lower in GL-AmBtreated cells after 4 and 6 h (~5 and~3-fold lower, respectively) compared to AmB-treated cells (P<0.001, Figure  7A ). However, this reduction was nonsignificant after 12 h (~1.6-fold) of treatment, indicating, again, higher early uptake of AmB in promastigotes after GL-AmB treatment ( Figure 7A ). This observation was also consistent with the measured difference in protein carbonylation which is a measure of oxidative stress-mediated damage caused by AmB. 50 Protein carbonylation was higher in GL-AmBtreated cells after 6 h (~1.6-fold) but almost similar after 12 h (<1.2-fold) compared to AmB-treated cells ( Figure  S9A and B) . Similarly, the increase in ROS ( Figure S8A ) and lipid peroxidation products ( Figure S9C ), which can be abrogated by pretreatment with ROS scavenger NAC, were significantly higher in GL-AmB-treated than AmBtreated cells after 6 h. Due to high similarity in observed results of GL-treated and GNP-treated samples, in most cases, the results for GL-treated samples were omitted. Trypanathione reductase (TryR) is involved in biosynthesis of trypanathione (major thiol of Leishmania along with glutathione) and maintaining the reduced status of LD under oxidative stress. The relative mRNA level of TryR and superoxide dismutase (SOD) were significantly lower ( Figure S10A ) and SOD enzyme activity was also reduced in GL-AmB-treated cells compared to AmB-treated cells ( Figure S10B ). We found~3.1 and~2.1-fold reduction in the TryR mRNA level for GL-AmB and AmB-treated promastigotes, respectively. Treatment of GNPs also showed~1.8-fold reduction in TryR expression which is consistent with the observation that the amount of ROS produced by GNPs and AmB-treated cells is comparable ( Figure  S8A ). Interestingly, selected gold complexes have earlier shown potential as antileishmanial agents by targeting trypanathione reductase. 86 For SOD, the reduction in mRNA level for GL-AmB and AmB-treated cells was 2.63 and~1.8-fold, respectively ( Figure S10B ). Consistent with observed higher reactive nitrogen species in GL-AmB-treated cells ( Figure S8B ), inducible nitric oxide synthase expression was also~2.85 and 1.75-fold up-regulated ( Figure S10C ) in GL-AmB and AmB-treated amastigotes, respectively. Expression of ascorbate peroxidase (APX) in AmB-resistant LD strain 87 and expression of heat shock protein in human epithelial cells after AmB-conjugated NP treatment 88 were found to be elevated. However, no significant changes were observed for APX and HSP-70 mRNA expression level after GL-AmB/AmB treatments compared to untreated control. The expression level of lanosterol-14-α-demethylase (Ldem) mRNA was~2.1 and~1.6-fold reduced in GL-AmB and AmBtreated cells, respectively. However, the expression level of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA, which is related to mevalonate biosynthesis and not directly related to ERG biosynthesis, was unchanged under similar treatment conditions ( Figure S10A ). The expression level of arginase 1, involved in the polyamine biosynthesis pathway, does not show any change after GLAmB/AmB treatment compared to untreated control. In short, the difference between the level of ROS, oxidized protein carbonyl, and reduced glutathione content in GLAmB and AmB-treated cells correlated well with observed changes in mRNA expression for genes involved in the oxidative stress response and ERG biosynthesis pathway of LD ( Figure S10A ). This shows that GL-AmB and AmB kills parasites through a common mechanism of action involving oxidative stress and the ERG biosynthesis pathway.
There was a marked increase in LDH release ( Figure  7C ) consistent with increased membrane fluidity ( Figure  7B ) in GL-AmB-treated parasites. This is a pattern similar to necrosis. Similarly, an increase in PI + cells with a concomitant decrease in AV + cells (higher PI + /AV + ratio in Figure 8C ) and lack of fragmented DNA ( Figure 8B ) indicated an enhanced necrotic mode of death of LD after GL-AmB treatment compared to AmB treatment. Interestingly, the ratio of PI + /AV + cells was very similar for GNP and AmB-treated cells, indicating a possible necrotic mode of death induced by citrate-reduced GNPs as well. VL is known to be associated with a mixed T h 1-T h 2 cytokine response. AmB-treated patients corresponded with an elevation in T h 1 and down-regulation of T h 2 cytokines. 89 GL-AmB, compared to AmB, significantly increased the level of T h 1 (IL-12, IFN-γ) and significantly reduced the level of T h 2 (IL-10) cytokines as measured by cytokine ELISA (Figure 9A -C) or by semiquantitative PCR for cytokine mRNAs ( Figure 9D) . Importantly, the change in released T h 1 and T h 2 level for GL-AmB-treated cells compared to AmB-treated cells is more significant at earlier time points (ie, 12, 24, and 48 h) and became insignificant after 72 h. Genes specific for T h 1 (IFN-γ, IL-12) and T h 2 (Il-10) cytokines showed significant changes in expression level between untreated and treated cells. The IFN-γ level was~3.2 and~1.9-fold up-regulated in GL-AmB and AmB-treated cells, respectively, compared to untreated control. For IL-12, the up-regulation was~2.5 and~2.0-fold under the same conditions. For IL-10, the mRNA level was down-regulated by~2.3 and 1.7-fold in GL-AmB and AmB-treated cells, respectively, compared to untreated control. For GNP, we found ~2.4-fold up-regulation of IFN-γ but no significant change in IL-12 mRNA level compared to untreated control. Therefore, semiquantitative PCR data ( Figure 9D ) correlate well with the cytokine ELISA data ( Figure 9A-C) .
Conclusion
Earlier, our coworkers showed a GNP-based detection method for measuring LD RNA in amastigote-infected macrophages. 90 They identified a drug-resistant LD strain based on GNP-based detection of single nucleotide polymorphism associated with resistance. 91 In parallel, hemoglobin-guided 92 and macrophage membranederived 93 nanovesicles for AmB delivery were developed for improved antileishmanial efficacy. In this study, efficacy of a synthesized gold nanoparticle-lipoic acid-amphotericin B (GL-AmB) covalent conjugate was evaluated compared to standard AmB against LD promastigote and amastigote forms. GL-AmB showed enhanced AmB uptake inside macrophages leading to higher production of reactive nitrogen species and an increased immunostimulatory effect measured by elevated T h 1 and decreased T h 2 cytokine levels. GL-AmB caused severe membrane damage leading to necrosis, increased extracellular release of LDH through porous membranes, marked depletion in ergosterol, and reduced thiol content. This is paralleled with higher production of ROS, lipid peroxides, and oxidized protein carbonyls in GL-AmB-treated parasites compared to AmB-treated parasites. In conclusion, the mechanism of action of GLAmB and AmB are very similar (Figure 10 ). However, GNP-based formulation of AmB is advantageous due to its enhanced antileishmanial activity, reduced toxicity, high macrophage uptake, increased immunostimulatory effect, and marked depletion in ERG content of parasite membranes leading to increased fluidity. In addition, we have found a possible mechanism of action of citratereduced GNP against LD. The high toxicity and hemolytic activity of both citrate-reduced GNP and AmB were significantly reduced following conjugation of AmB with GNP. Therefore, GNP-based formulation of AmB may replace available formulations of AmB in future, and synthesis of new GNP-based conjugates with other antileishmanial or antifungal agents may give us new insights into GNP-based drug delivery. 
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